2:37 PM
Jul 10, 2018
 |  BC Innovations  |  Distillery Therapeutics

Infectious disease


Mouse studies suggest IL-33 or inhibiting NLRP3 could help treat cerebral malaria. In a mouse model of Plasmodium berghei-induced cerebral malaria treated with artesunate and chloroquine, brain levels of IL-33 were lower and brain levels of NLRP3 were higher seven days...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >